Cost analysis of GenoType® MTBDRplus and GenoType® MTBDRsl at the State Laboratory of São Paulo, Brazil

Rev Soc Bras Med Trop. 2023 Jul 28:56:e0238-2023. doi: 10.1590/0037-8682-0238-2023. eCollection 2023.

Abstract

Background: We aimed to evaluate the costs of GenoType® MTBDRplus and MTBDRsl incurred during the diagnosis of first- and second-line drug-resistant tuberculosis (TB) in São Paulo, Brazil.

Methods: Mean and activity-based costs of GenoType® were calculated in a referral laboratory for TB in Brazil.

Results: The mean cost value and activity-based cost of GenoType® MTBDRplus were USD 19.78 and USD 35.80 and those of MTBDRsl were USD 54.25 and USD 41.85, respectively.

Conclusions: The cost of GenoType® MTBDRplus was reduced owing to the high number of examinations performed and work optimization.

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Brazil
  • Costs and Cost Analysis
  • Genotype
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis* / genetics
  • Sensitivity and Specificity
  • Tuberculosis, Multidrug-Resistant* / diagnosis
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents